Are pharma profits excessive?

From Quora: “Excessive” is loaded term. Worse, it’s subjective and difficult to define. Let’s see if we can put it into some kind of context or framework that permits a useful discussion. Congress, always sensitive to public resentment over drug prices, had the GAO do a study on drug company profitability. The 1-page summary, which you should definitely Read More …

Making antibiotic development great again: has the code been cracked for narrow-spectrum agents?

Once in a while you see an idea that is both so brilliant and so obvious that you just have to smack your head and ask “Why has no one thought of this before? Why didn’t I think of it?”. There’s a general consensus that broad-spectrum antibiotics are over-used. The consequences are many and egregious: Read More …

Why aren’t all those breakthroughs translating into cures?

One of the ways that science journalism continually fails the public is by ignoring the Valley of Death that lies between discovery and product development. The problem is especially acute in healthcare, where the maddening complexity and unpredictability of clinical responses dooms most “breakthroughs” to failure. The problem is less ignorance on the part of Read More …

Is it right that less-developed economies are deprived access to technological advances?

Innovations created in developed economies do not deprive less-developed economies of anything. More to the point, less-developed economies eventually get access to these innovations, and get them at prices that are cheaper than the prevailing prices in developed economies. Drugs are a good example of this dynamic. Many of us consider new drug prices to Read More …